Atea Pharmaceuticals, Inc. (AVIR) Key Metrics
AVIR valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $346.5M
- Enterprise value
- $204.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 1.6 10-yr median 2.2
- Price / book
- 2.1 10-yr median 0.8
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.39
AVIR key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsAVIR valuation Price multiples at each fiscal year-end price.
AVIR returns How much profit the business earns on the capital it uses.
AVIR per-share figures Results divided by the shares outstanding at year-end.
AVIR financial health Debt, liquidity and how easily interest is covered.
AVIR efficiency & capital use Working capital cycle and where the cash goes.
AVIR valuation history
AVIR returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
AVIR debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
AVIR cash returned to shareholders
AVIR price vs earnings per share
AVIR key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $290.9M | $282.3M | $254.3M | $400.4M | $788.9M | $3.44B | — | — |
| Enterprise value | −$10.0M | −$170.8M | −$321.4M | −$243.2M | $24.8M | $2.59B | — | — |
| P/E ratio | — | — | — | — | 6.5 | — | — | — |
| Price / sales | — | — | — | 2.1 | 2.2 | 70.8 | — | — |
| Price / book | 1.1 | 0.6 | 0.5 | 0.6 | 1.1 | 6.3 | — | — |
| Price / free cash flow | — | — | — | — | — | 11.6 | — | — |
| Price / operating cash flow | — | — | — | — | — | 11.6 | — | — |
| EV / sales | — | — | — | -1.3 | 0.1 | 53.3 | — | — |
| EV / EBITDA | — | — | — | — | 0.2 | — | — | — |
| EV / free cash flow | — | — | — | — | — | 8.7 | — | — |
| Earnings yield | −54.4% | −59.7% | −53.5% | −28.9% | 15.4% | −0.3% | — | — |
| Free cash flow yield | −45.4% | −48.0% | −33.6% | −30.7% | −11.0% | 8.6% | — | — |
| Shareholder yield (dividends + buybacks) | 8.8% | 0.0% | — | — | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $3.57 | $3.35 | $3.05 | $4.81 | $8.94 | $41.78 | — | — |
| Per share | ||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $2.31 | $3.98 | $0.59 | $0.00 | — |
| Earnings per share | −$1.94 | −$2.00 | −$1.63 | −$1.39 | $1.37 | −$0.13 | −$0.16 | — |
| Operating cash flow per share | −$1.62 | −$1.61 | −$1.02 | −$1.45 | −$0.99 | $3.60 | −$0.16 | — |
| Free cash flow per share | −$1.62 | −$1.61 | −$1.02 | −$1.48 | −$0.99 | $3.60 | −$0.16 | — |
| Cash per share | $3.70 | $5.40 | $6.93 | $7.77 | $8.66 | $10.31 | $0.26 | — |
| Book value per share | $3.38 | $5.21 | $6.66 | $7.69 | $8.05 | $6.65 | −$0.60 | — |
| Tangible book value per share | $3.38 | $5.21 | $6.66 | $7.69 | $8.05 | $6.65 | −$0.60 | — |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.02 | $0.00 | $0.00 | $0.00 | — |
| Debt per share | $0.01 | $0.02 | $0.03 | $0.04 | $0.00 | — | $0.00 | — |
| Shares outstanding | 81.5M | 84.3M | 83.4M | 83.2M | 88.2M | 82.4M | 82.6M | — |
| Change in shares outstanding | −3.3% | +1.0% | +0.2% | −5.7% | +7.1% | −0.2% | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −44.3% | −33.9% | −22.7% | −17.2% | 19.3% | −4.4% | — | — |
| Return on assets (ROA) | −40.6% | −31.8% | −21.6% | −16.1% | 14.8% | −2.5% | −47.3% | −26.0% |
| Return on tangible assets | −50.2% | −36.2% | −22.9% | −17.4% | 15.7% | −1.3% | −61.0% | −26.0% |
| Free cash flow margin | — | — | — | −64.0% | −24.8% | 610.1% | — | — |
| Income quality (OCF / net income) | — | — | — | — | −0.72 | — | — | — |
| Financial health | ||||||||
| Total debt | $843,000 | $1.6M | $2.4M | $3.1M | $197,000 | — | $200,000 | −$200,000 |
| Cash & short-term investments | $301.8M | $454.7M | $578.1M | $646.7M | $764.4M | $850.1M | $21.7M | $34.5M |
| Net debt | −$301.0M | −$453.1M | −$575.7M | −$643.6M | −$764.2M | −$850.1M | −$21.5M | −$34.7M |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Debt / assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.01 | −0.01 |
| Net debt / EBITDA | — | — | — | — | −5.52 | — | — | — |
| Current ratio | 7.82 | 24.85 | 18.24 | 35.77 | 13.58 | 2.73 | 9.00 | 19.71 |
| Quick ratio | 7.82 | 24.85 | 18.24 | 35.77 | 13.58 | 2.73 | 9.00 | 19.71 |
| Interest coverage | — | — | — | -11.7 | 571.8 | -132.9 | — | — |
| Working capital | $271.2M | $443.8M | $558.1M | $642.4M | $715.5M | $547.7M | $19.5M | $32.9M |
| Invested capital | −$25.6M | −$14.2M | −$20.5M | −$3.0M | −$54.1M | −$302.3M | −$71.0M | −$70.9M |
| Tangible asset value | $275.4M | $438.9M | $555.2M | $640.6M | $710.1M | $547.8M | −$49.6M | −$36.2M |
| Net current asset value | $271.2M | $436.6M | $550.7M | $634.8M | $709.6M | $547.6M | −$49.7M | −$36.3M |
| Graham number | — | — | — | — | $15.77 | — | — | — |
| Graham net-net per share | $3.22 | $5.09 | $6.46 | $7.45 | $7.95 | $6.53 | −$0.60 | — |
| Capital allocation | ||||||||
| Share buybacks (net) | $25.5M | $0 | — | — | $0 | $0 | — | — |
| Dividends + buybacks / free cash flow | — | — | — | — | — | 0.0% | — | — |
| Capex / revenue | — | — | — | 1.0% | 0.0% | 0.1% | — | — |
| Capex / operating cash flow | — | — | — | — | — | 0.0% | — | — |
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 7.47 | 0.14 | 1.37 | 0.12 | 0.71 |
| Stock-based compensation / revenue | — | — | — | 24.3% | 11.3% | 15.3% | — | — |
| R&D / revenue | — | — | — | 42.6% | 47.6% | 78.2% | — | — |
| SG&A / revenue | — | — | — | 25.3% | 13.0% | 44.5% | — | — |
| Efficiency | ||||||||
| Days sales outstanding | — | — | — | — | — | 43.6 | — | — |
| Days payables outstanding | 7,634.7 | 19.1 | 17.7 | 4,973.1 | 28,910.5 | 2.9 | 10,080.4 | 8,395.0 |
| Cash conversion cycle (days) | — | — | — | — | — | 40.7 | — | — |
| Receivables turnover | — | — | — | — | — | 8.36 | — | — |
| Payables turnover | 0.05 | 19.14 | 20.61 | 0.07 | 0.01 | 125.08 | 0.04 | 0.04 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.27 | 0.43 | 0.11 | 0.00 | 0.00 |
| Average receivables | — | — | — | — | — | $5.8M | — | — |
| Average payables | $8.7M | $4.4M | $3.4M | $3.5M | $2.3M | $304,000 | $469,500 | $391,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from AVIR's annual financial statements (latest annual report filed March 5, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
AVIR valuation and financial ratios
Atea Pharmaceuticals earned a return on equity of −44.3% in fiscal 2025. It ended the year with $0.8 million of debt and $301.8 million in cash and short-term investments, a net cash position of $301.0 million. It returned $25.5 million to shareholders: $0 in dividends and $25.5 million in share buybacks.
See the AVIR income statement, the AVIR chart for price history, or the AVIR stock overview for the latest quote and news.
AVIR key metrics FAQ
What is Atea Pharmaceuticals's return on equity?
Atea Pharmaceuticals's return on equity (ROE) was −44.3% in fiscal 2025: net income of -$158.3 million on average shareholders' equity of $357.2 million.
How much debt does Atea Pharmaceuticals have?
Atea Pharmaceuticals had total debt of $0.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
Does Atea Pharmaceuticals buy back its shares?
Yes. Atea Pharmaceuticals spent $25.5 million on net share repurchases in fiscal 2025 Shares outstanding changed −3.3% over the year, to 81.5M..
What is Atea Pharmaceuticals's free cash flow yield?
Atea Pharmaceuticals generated -$132.0 million of free cash flow in fiscal 2025, a free cash flow yield of −45.4% on its market value at year-end ($290.9 million).
What is Atea Pharmaceuticals's current ratio?
Atea Pharmaceuticals's current ratio was 7.82 at the end of fiscal 2025: current assets were 7.82 times current liabilities.